REZOLUTE INC. - COMMON STOCK (NV)

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

07 Jan 2025 08:00:01 By Nasdaq GlobeNewswire

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

05 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

03 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

07 Nov 2024 16:05:02 By Nasdaq GlobeNewswire

Rezolute to Participate in Upcoming Investor Conferences

05 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

19 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

09 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Rezolute to Participate in Upcoming Investor Conferences

27 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

05 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

31 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

27 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

24 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

13 Jun 2024 23:30:00 By Nasdaq GlobeNewswire

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

13 Jun 2024 16:01:00 By Nasdaq GlobeNewswire

Rezolute to Participate in the Jefferies Global Healthcare Conference

30 May 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

21 May 2024 16:05:00 By Nasdaq GlobeNewswire

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

15 May 2024 16:05:00 By Nasdaq GlobeNewswire

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

23 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

06 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

13 Feb 2024 16:05:00 By Nasdaq GlobeNewswire